Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Poster Session

Periodic Fever Syndromes, Autoinflammatory Diseases, Still’s Disease and MAS/HLH

Poster Session B

Session: (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

1190: IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort

Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Location: Hall F1

    Abstract Poster Presenter(s)

  • XY

    Xinli Yang, MD

    Peking Union Medical College
    Dong Cheng Qu, Beijing, China

    Disclosure(s): No financial relationships with ineligible companies to disclose


Background/Purpose: This study aimed to explore the clinical characteristics, treatment, and prognosis of IgG4-related disease (IgG4-RD) patients with comorbid autoimmune diseases (AIDs).

Methods: A total of 879 treatment naïve IgG4-RD patients from Peking Union Medical College Hospital were retrospectively included in this study. IgG4-RD Patients with comorbid autoimmune diseases were classified into the AID-positive (AID-Pos) subgroup, while those without autoimmune diseases were classified into the AID-negative (AID-Neg) subgroup. Additionally, AIDs were classified as systemic or organ-specific. The clinical features, laboratory findings, treatment regimens, and long-term prognosis were compared among the AID-Pos and AID-Neg groups, and the characteristics of AIDs were also explored.

Results: The prevalence rate of AIDs in IgG4-RD patients was 9.67% (85/879), including 47 cases of systemic AIDs and 38 cases of organ-specific AIDs. The types of comorbid AIDs were diverse, such as vitiligo (15 patients), systemic vasculitis (12 patients), psoriasis (12 patients), Hashimoto’s thyroiditis (11 patients), and rheumatoid arthritis (10 patients). Most AIDs occurred before or simultaneously with IgG4-RD. Among AID-Pos subgroup patients, 75 (88.2%) had only one type of AID. AID-Pos subgroup patients had lower serum IgG4 levels than AID-Neg subgroup patients (6017 [2729;13900] vs 9176 [3956;18100], p=0.004). Compared with AID-Neg subgroup patients, those with systemic AIDs had higher level of erythrocyte sedimentation rate (40 [22.5; 74.] vs 18.0 [10.0;52.0] mm/hr, adjusted p < 0.001) and higher serum IgG1 level (11500 [8355;13575] vs 8700 [7215;11000] mg/L, adjusted p=0.002). There was no significant difference in treatment regimens and long-term prognosis between AID-Pos and AID-Neg subgroup patients.

Conclusion: IgG4-RD patients can complicate with other AIDs. Compared with AID-neg subgroup patients, IgG4-RD patients with comorbid AIDs have lower serum IgG4 levels, while the clinical characteristics, treatment, and prognosis were similar between two subgroups.